Arovella Therapeutics (ASX:ALA)
ASX announcement history & article coverage
Transparent by design.
Announcments by Arovella Therapeutics (ASX:ALA) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Arovella receives R&D tax rebate of $4.03 million
Arovella receives $4.03 million R&D tax refund to support clinical programs
Second Clinical Batch Released for Immediate Patient Use
Arovella releases second ALA-101 clinical batch ahead of Phase 1 expansion
Cell and Gene Innovation Spotlight Presentation
Notice of Annual General Meeting/Proxy Form
The path to first patient dosing
Arovella expects first ALA-101 patient dosing by late October
2026 ESG Report
Notification of 2026 AGM Date
Clinical manufacturing batch released, first site activated
Arovella releases first clinical batch of ALA-101 and activates first trial site
Corporate Governance Statement
Appendix 4G
Appendix 4E and Annual Report
Arovella Therapeutics advances CAR-iNKT clinical trials with FY26 loss narrowing to $6.9M
Notification regarding unquoted securities - ALA
Investor Webinar Presentation
Investor Webinar Registration
Quarterly Activities/Appendix 4C Cash Flow Report
Arovella advances CAR-iNKT clinical trials and solid tumour program with strong cash position
